Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 487 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Mapping Cancer Genomic Evolution Offers Insights into Tumor Development March 6, 2020 EMA Recommends Additional Extensions of Indications for Pembrolizumab October 7, 2024 We want every scientist to thrive in cancer research July 28, 2023 ESMO Immuno-Oncology Virtual Congress 2020 November 30, 2020 Load more HOT NEWS Diving into our role in 50 top cancer drugs For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2...
